Table 1.
Subject demographic, clinical, and cognitive characteristics.
| 2020-GROUP N = 46 | 2019-GROUP N = 40 | 2018-GROUP N = 46 | p Value | |
|---|---|---|---|---|
| Age | 78.78 ± 8.82 | 79.58 ± 6.20 | 79.30 ± 6.21 | 0.919 |
| Sex (f/m) | 32/14 | 25/15 | 28/18 | 0.654 |
| Education in years | 6.96 ± 3.63 | 6.25 ± 2.69 | 6.43 ± 3.59 | 0.671 |
| Follow-up in years | 0.93 ± 0.15 | 0.95 ± 0.16 | 0.94 ± 0.15 | 0.912 |
| Disease duration in years | 4.33 ± 2.24 | 4.10 ± 1.98 | 3.96 ± 1.80 | 0.838 |
| MMSE T0 | 21.61 ± 4.75 | 20.20 ± 4.68 | 21.15 ± 3.36 | 0.370 |
| MMSE T1 | 18.56 ± 5.03 | 18.89 ± 5.24 | 19.94 ± 3.37 | 0.380 |
| Index of progression | −3.25 | −1.39 | −1.33 | 0.021 |
| Diagnosis N (%) | 0.836 | |||
| AD | 21 (46%) | 21 (53%) | 26 (57%) | |
| DLB | 1 (2%) | 2 (5%) | 1 (2%) | |
| FTD | 5 (11%) | 2 (5%) | 2 (4%) | |
| MCI | 10 (22%) | 7 (18%) | 6 (13%) | |
| VAD | 9 (20%) | 8 (20%) | 11 (24%) | |
| Therapy N (%) | 0.945 | |||
| None | 13 (28%) | 14 (35%) | 16 (35%) | |
| Donepezil | 14 (30%) | 8 (20%) | 11 (24%) | |
| Rivastigmine | 7 (15%) | 7 (18%) | 6 (13%) | |
| Donepezil + Memantine | 4 (9%) | 5 (13%) | 6 (13%) | |
| Other | 8 (17%) | 6 (15%) | 7 (15%) |
p-values denote significant difference among all groups on the Kruskal–Wallis test for continuous measures and from the Chi-squared test for categorical measures. Quantitative variables are described using mean ± standard deviation, while qualitative variables are expressed as numbers (percentage). N: number; f: female; m: male; MMSE: mini mental state examination; AD: Alzheimer’s disease; DLB: dementia with Lewy bodies; FTD: frontotemporal dementia; MCI: mild cognitive impairment; VAD: vascular dementia.